Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin C, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma

CardioVascular and Interventional Radiology

Volumn 35, Issue 6, 2012, Pages 1363-1371

  Sahara, Shinya ^a   Kawai, Nobuyuki ^a   Sato, Morio ^a   Tanaka, Takami ^a   Ikoma, Akira ^a   Nakata, Kouhei ^a   Sanda, Hiroki ^a   Minamiguchi, Hiroki ^a   Nakai, Motoki ^a   Shirai, Shintaro ^a   Sonomura, Tetsuo ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anticancer drugs; Cisplatin; Epirubicin; Hepatocellular carcinoma; Transcatheter arterial embolization

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; IODINATED POPPYSEED OIL; MITOMYCIN; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; IOHEXOL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BILE LEAKAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEPATIC ARTERY ABNORMALITY; HUMAN; IATROGENIC DISEASE; LIVER BLOOD FLOW; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTEMBOLIZATION SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH PERFORATION; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; VOMITING; ANGIOGRAPHY; BIOASSAY; CHI SQUARE DISTRIBUTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; LIVER FUNCTION TEST; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGRAPHY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; CISPLATIN; CONTRAST MEDIA; ENDPOINT DETERMINATION; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; IOHEXOL; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84875255955     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-012-0352-x     Document Type: Article

References (25)

1. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171
2. Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734-1739
3. Camma C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47-54
4. Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397-401
5. Chang JM, Tzeng WS, Pan HB et al (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74:2449-2453
6. Kawai S, Okamura J, Ogawa M et al (1992) prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: A comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 31(Suppl):S1-S6
7. Sahara S, Kawai N, Sato M et al (2001) Prospective comparison of transcatheter arterial chemoembolization with lipiodol-epirubicin and lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma. Jpn J Radiol 28:362-368
8. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25
9. Nishimine K, Uchida H, Matsuo N et al (1994) Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother Pharmacol 33(Suppl):S60-S68
10. Brown DB, Pilgram TK, Darcy MD et al (2005) Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16:1661-1666
11. Gomes AS, Rosove MH, Rosen PJ et al (2009) Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients. AJR Am J Roentgenol 193:1665-1671
12. Eisenhauer EA, Therasse P, Bogaerts LH et al (2009) New response evaluation criteria in solid tumours: Revised RECIST (version 1.1). EJC 45:228-247
13. Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35:421-430
14. Maeda N, Osuga K, Mikami K et al (2008) Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. Radiat Med 26:206-212
15. Ono Y, Yoshimasu T, Ashikaga R et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23:564-568
16. Yodono H, Matsuo K, Shinohara A et al (2011) A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial embolization for treatment of hepatocellular carcinoma. Anticancer Drugs 22:277-282
17. Yamanaka K, Hatano E, Narita M et al (2011) Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 41:303-309
18. Kamada K, Nakanishi T, Kitamoto M et al (2001) Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin Lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 12:847-854
19. Ichida T, Kato M, Hayakawa A et al (1992) Treatment of hepatocellular carcinoma with a CDDP-epirubicin-lipiodol suspension: a pilot clinico-pharmacological study. Cancer Chemother Pharmacol 31(Suppl):S51-S54
20. Kawai S, Tani M, Okamura J et al (1997) Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 24(S6):38-45
21. Sato M, Yamada R, Uchida B et al (1993) Effects of hepatic artery embolization with lipiodol and gelatin sponge particles on normal swine liver. Cardiovasc Intervent Radiol 16:348-354
22. Masuda M (2002) Evaluation of basic and clinical study on effect of anticancer drugs of lipiodol in chemoembolization on liver tissue. J Wakayama Med Soc 53:185-192
23. Sahara S, Tanihata H, Sato M et al (2009) Effects of hepatic artery chemoembolization using cisplatin-lipiodol suspension with gelatin sponge particles on swine liver. J Vasc Interv Radiol 20:1359-1364
24. Kim HK, Chung YH, Song BC et al (2001) Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 32:423-427
25. Sueyoshi E, Hayashida T, Sakamoto I et al (2010) Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Am J Roentgenol 195:245-251